GlassScriptPhysician profile
Roberto L Duran
NPI 1619915964
$7,840.20
in general payments reported to CMS, 2019-2025
53 companies · $903 in 2025
The $903 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,244 · 2020: $354 · 2021: $923 · 2022: $2,329 · 2023: $938 · 2024: $1,150 · 2025: $903.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,991.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,990.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mml US, INC. | $1,570.31 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $709.01 | 2019-2025 | Relistor |
| Abbvie INC. | $688.61 | 2021-2025 | Ubrelvy, Qulipta |
| Pfizer INC. | $666.86 | 2019-2025 | |
| Horizon Therapeutics Plc | $311.46 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $301.13 | 2019-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Abbott Laboratories | $285.25 | 2019-2022 | |
| Emd Serono, INC. | $226.46 | 2019-2025 | |
| Collegium Pharmaceutical, INC. | $181.44 | 2019-2024 | Xtampza |
| Amneal Pharmaceuticals LLC | $174.13 | 2021-2025 | Crexont, Ongentys |
| Biohaven Pharmaceutical Holding Company LTD. | $162.56 | 2022 | |
| Mdd US Operations, LLC | $156.12 | 2019-2020 | |
| Allergan, INC. | $151.54 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $140.67 | 2020-2021 | |
| Neurocrine Biosciences, INC. | $139.27 | 2024-2025 | Ingrezza |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Duran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.